Topically absorbable compositions with bioactive or bioavailable cannabis-derived cannabinoids known to be effective for CB1 or CB2 modulation, and a plurality of indications for patients in need, and methods for producing composition, without detectable or biologically active levels of THC. Method uses a heat cycle process to combine cannabinoids with flax seed oil and at least one triglyceride, to produce an extract. The extract can include non-psychoactive agents, namely, CBD and accordingly does not deleteriously impact federal legal schemes or bone fide drug-testing regimes.
